12:00 AM
 | 
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Votrient pazopanib regulatory update

The European Commission approved Votrient pazopanib from GlaxoSmithKline to treat advanced soft tissue sarcoma in patients who received prior chemotherapy...

Read the full 78 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >